Managing Spotting After 1 Year of Nexplanon Use

Initial Assessment and Treatment

The Centers for Disease Control and Prevention recommends ruling out underlying gynecological problems, such as pregnancy, sexually transmitted infections, medication interactions, and structural pathology, before initiating treatment for spotting after 1 year of Nexplanon use 1, 2
The American College of Obstetricians and Gynecologists suggests performing a pregnancy test if clinically indicated, especially if the bleeding pattern changed abruptly, to rule out pregnancy 1, 3
The World Health Organization recommends screening for STDs that can alter bleeding patterns 1, 3
The Centers for Disease Control and Prevention advises reviewing all current medications for potential interactions 1, 2

The American College of Obstetricians and Gynecologists recommends mefenamic acid 500 mg three times daily for 5 days during active bleeding as a first-line treatment for spotting after 1 year of Nexplanon use 2, 3
The Centers for Disease Control and Prevention suggests celecoxib 200 mg daily for 5 days during active bleeding as an alternative first-line treatment 2, 3
The World Health Organization recommends low-dose combined oral contraceptives for 10-20 days as a second-line treatment if NSAIDs fail and bleeding persists 1, 2, 3
The American College of Obstetricians and Gynecologists advises counseling on alternative contraceptive methods if bleeding persists despite treatment and remains unacceptable to the patient 1, 2, 4

The Centers for Disease Control and Prevention notes that spotting after 1 year of Nexplanon use is common but generally not harmful, with clinical trial data showing that 34% of etonogestrel implant users experience infrequent spotting, while 7% report frequent bleeding and 18% report prolonged bleeding 1, 2
The American College of Obstetricians and Gynecologists suggests that enhanced counseling about expected bleeding patterns can reduce discontinuation rates with hormonal contraceptives 1, 2, 5

The World Health Organization advises against assuming functional bleeding without excluding structural pathology, especially in women over 35 where polyps and fibroids are more common 4
The Centers for Disease Control and Prevention recommends against initiating treatment without first ruling out pregnancy, STDs, and medication interactions 1, 2, 3
The American College of Obstetricians and Gynecologists warns against prescribing combined hormonal contraceptives without verifying medical eligibility due to thromboembolism risk 3